Hu-manity.co, which develops consent and authorization management technology for human data, has publicly announced the acquisition of Betterpath, which develops technology that gives patients hard-to-access healthcare data. The company says its Consumer Consent as a Service will give people healthcare’s untapped datasets, also dubbed healthcare’s dark data.
Hu-manity.co has a #My31 app for Apple and Android that allows people to request deep clinical datasets from hospitals, clinics, and laboratories which are often still on paper, behind fax machines and unstructured. The firm explained that its blockchain-backed consent and authorization management platform, together with Betterpath’s Compass, Sonar, and Lumos technologies, is able to find and deliver some of the 80 percent of healthcare data that they say is not available to patients, providers, and clinical researchers.
“The track and trace of consent and authorization model that Hu-manity.co has brought to market has been what is missing in healthcare data from the inception,” commented Matt Sinderbrand, CEO and co-founder of Betterpath and now Senior Vice President and Chief Product Officer at Hu-manity.co in a statement. “The simple idea that we should put the consumer (the patient) into the center of the healthcare data supply chain with ownership rights literally at their fingertips is both powerful, and timely.”
The executive says the training of Betterpath’s Lumos technology to learn more than 100,000 biomedical-terms, synonyms, relationships, and structured codes was inspired by witnessing a family member struggle to access her own healthcare data while living with Crohn's disease.
The Betterpath technology – which enables “Fair Trade Data” practice – operates using Amazon Web Services, React, Datomic, Docker, Cassandra, and Scala wrapped by fax automation, real time APIs, trained Optical Character Recognition, the NPI database, the Unified Medical Language System, and a patented process of medical natural language training and understanding.
Hu-manity.co says the acquisition brings two more patents to its intellectual property portfolio and also operates an IRB-approved observational research cohort that enables healthcare’s dark data to be used for FDA regulated clinical trials.
